Trials / Unknown
UnknownNCT00385125
Treatment of Patients With Relapsed or Primary Refractory Aggressive B- Cell NHL
Phase II Study for Treatment of Patients With Relapsed or Primary Refractory Aggressive B- Cell NHL and Anthracycline Chemotherapy Pretreatment, Who Received or Did Not Qualify for Autologous Stem Cell Transplantation.
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (planned)
- Sponsor
- University of Magdeburg · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Phase II study for treatment of patients with relapsed or primary refractory aggressive B- cell NHL and anthracycline chemotherapy pretreatment, who received or did not qualify for autologous stem cell transplantation.
Detailed description
Phase II study for treatment of patients with relapsed or primary refractory aggressive B- cell NHL and anthracycline chemotherapy pretreatment, who received or did not qualify for autologous stem cell transplantation. Aim is to find response rates and duration of combination chemotherapy (bendamustine/rituximab) in patients with relapsed or refractory CD 20 positive B cell NHL.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bendamustine | |
| DRUG | Rituximab |
Timeline
- Start date
- 2004-08-01
- Completion
- 2010-08-01
- First posted
- 2006-10-06
- Last updated
- 2006-10-06
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT00385125. Inclusion in this directory is not an endorsement.